Insider Transactions in Q1 2022 at Recursion Pharmaceuticals, Inc. (RXRX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2022
|
Ramona Doyle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,072
+6.92%
|
$18,144
$2.48 P/Share
|
|
Mar 15
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,150
-2.56%
|
$36,900
$6.08 P/Share
|
|
Mar 15
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
6,150
+2.5%
|
-
|
|
Mar 14
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
230,000
-49.57%
|
$1,380,000
$6.28 P/Share
|
|
Mar 14
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
230,000
+33.14%
|
-
|
|
Mar 11
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-29.94%
|
$600,000
$6.95 P/Share
|
|
Mar 11
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+23.04%
|
-
|
|
Mar 07
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
300,000
-56.18%
|
$2,100,000
$7.3 P/Share
|
|
Mar 07
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
300,000
+35.97%
|
-
|
|
Mar 04
2022
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
58,500
+21.95%
|
$58,500
$1.06 P/Share
|
|
Feb 28
2022
|
Ramona Doyle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+12.16%
|
$31,250
$2.48 P/Share
|
|
Feb 22
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-29.94%
|
$1,000,000
$10.22 P/Share
|
|
Feb 22
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+23.04%
|
-
|
|
Feb 18
2022
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+9.67%
|
$16,000
$1.06 P/Share
|
|
Feb 14
2022
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+2.91%
|
$4,000
$1.06 P/Share
|
|
Feb 04
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
343
-0.15%
|
$3,773
$11.4 P/Share
|
|
Feb 04
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
210,893
+24.24%
|
-
|
|
Feb 04
2022
|
Tina Marriott Larson President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
828
-0.64%
|
$9,108
$11.4 P/Share
|
|
Feb 04
2022
|
Tina Marriott Larson President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
82,005
+20.08%
|
-
|
|
Feb 04
2022
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
678
-0.11%
|
$7,458
$11.4 P/Share
|
|
Feb 04
2022
|
Michael Secora Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,299
+4.67%
|
-
|
|
Feb 04
2022
|
Ramona Doyle Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
981
-1.0%
|
$10,791
$11.4 P/Share
|
|
Feb 04
2022
|
Ramona Doyle Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,891
+15.52%
|
-
|
|
Feb 04
2022
|
Shafique Virani Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,114
-1.05%
|
$12,254
$11.4 P/Share
|
|
Feb 04
2022
|
Shafique Virani Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,943
+15.22%
|
-
|
|
Jan 31
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,858
-45.83%
|
$218,438
$11.73 P/Share
|
|
Jan 31
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
19,858
+31.43%
|
-
|
|
Jan 31
2022
|
Ramona Doyle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+21.42%
|
$31,250
$2.48 P/Share
|
|
Jan 14
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
254,000
-91.54%
|
$3,302,000
$13.57 P/Share
|
|
Jan 14
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
254,000
+47.79%
|
-
|
|
Jan 13
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
87,000
-49.03%
|
$1,218,000
$14.61 P/Share
|
|
Jan 13
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
87,000
+44.06%
|
-
|
|
Jan 04
2022
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
9,625
-0.13%
|
$173,250
$18.03 P/Share
|
|
Jan 03
2022
|
Zachary Bogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
589
+30.07%
|
-
|
|
Jan 03
2022
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
555
+0.01%
|
-
|
|
Jan 03
2022
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
763
+0.56%
|
-
|
|
Jan 03
2022
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+10.71%
|
-
|
|
Jan 03
2022
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
693
+8.1%
|
-
|
|
Jan 03
2022
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
659
+0.11%
|
-
|
|
Jan 03
2022
|
Ramona Doyle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,322
+50.0%
|
$80,644
$2.47 P/Share
|